Research programme: anti-MUC1 antibodies - BiomiraAlternative Names: Anti-MUC1 antibodies research programme - Biomira
Latest Information Update: 10 Sep 2004
At a glance
- Originator Biomira
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Autoimmune disorders
Most Recent Events
- 10 Sep 2004 Discontinued - Preclinical for Autoimmune disorders in USA (unspecified route)
- 25 Jun 2003 Suspended - Preclinical for Autoimmune disorders in USA (unspecified route)
- 07 Dec 1999 Preclinical development for Autoimmune disorders in USA (Unknown route)